Premium
Anti‐CGRP monoclonal antibodies: breakthrough in migraine therapeutics
Author(s) -
Krishnaswamy Ratna,
Malik Bilal Haider,
Khan Safeera,
Gupta Deepti,
Islam Muhammad,
Mandal Shrawan Kumar,
Rutkofsky Ian H
Publication year - 2019
Publication title -
progress in neurology and psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.19
H-Index - 12
eISSN - 1931-227X
pISSN - 1367-7543
DOI - 10.1002/pnp.544
Subject(s) - calcitonin gene related peptide , migraine , medicine , calcitonin , monoclonal antibody , pathophysiology , neuroscience , antibody , bioinformatics , immunology , neuropeptide , psychology , receptor , biology
Migraine is considered as one of the most debilitating neurological disorders but the success of the anti‐calcitonin gene‐related peptide (CGRP) therapies marks a new era in the treatment of migraine and has paved way for further research into the exact pathophysiology of migraine. Here, the authors discuss their literature review on the anti‐CGRP therapies to examine the pathophysiology of migraine, with a focus on the possible role of CGRP and the safety and efficacy of monoclonal antibodies targeting it.